Top Institute Pharma (TIP) - research UMCU-rheumatology: Metabolic adverse events/co-morbidity in chronic rheumatoid arthritis patients

Top Institute Pharma (TIP) - research UMCU-rheumatology: *Metabolic adverse events/co-morbidity in chronic rheumatoid arthritis patients* - Top Institute Pharma (TIP) - research UMCU-rheumatology

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32316

Enrollment

300

Registered

2008-06-24

Start date

2008-07-28

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes rheumatism

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosis reumatoïd arthritis with disease duration > 2 years.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Metabolic syndrome according to the WHO-criteria (incl. insulin resistence), e.g. insulin resistence and 2 of the following criteria: dyslipidemia, hypertension or central obesity.	—

Secondary

Measure	Time frame
Secundary: Insuline resistence pattern measured over 2 hours with a 7-point OGTT. Co-variables: Other cardiovascular risk factors and disease activity of RA.	—

Countries

Netherlands

Outcome results